{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:08Z","timestamp":1791304328249,"version":"4.3.1"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T00:00:00Z","timestamp":1440460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR057643"],"award-info":[{"award-number":["R01AR057643"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1111\/bjd.14016","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T11:36:27Z","timestamp":1436182587000},"page":"641-650","source":"Crossref","is-referenced-by-count":88,"title":["Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo"],"prefix":"10.1093","volume":"173","author":[{"given":"K.C.","family":"Webb","sequence":"first","affiliation":[{"name":"Department of Dermatology; Loyola University Stritch School of Medicine; 2160 South First Ave Maywood IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Loyola University Stritch School of Medicine; 2160 South First Ave Maywood IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Winterfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Loyola University Stritch School of Medicine; 2160 South First Ave Maywood IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tufts University Medical Center; Boston MA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Eby","sequence":"additional","affiliation":[{"name":"Oncology Research Institute; Loyola University Chicago; IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Henning","sequence":"additional","affiliation":[{"name":"Oncology Research Institute; Loyola University Chicago; IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.C.","family":"Le Poole","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Microbiology and Immunology; Loyola University Stritch School of Medicine; 2160 South First Ave Maywood IL U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"10.1111\/bjd.14016-BIB0001|bjd14016-cit-0001","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0190-9622(91)70102-8","article-title":"Tumor necrosis factor","volume":"24","author":"Wakefield","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14016-BIB0002|bjd14016-cit-0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev.iy.10.040192.002211","article-title":"The pathophysiology of tumour necrosis factor","volume":"10","author":"Vassali","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/bjd.14016-BIB0003|bjd14016-cit-0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signaling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/bjd.14016-BIB0004|bjd14016-cit-0004","first-page":"3","article-title":"Genomic structure, induction, and production of TNF-alpha","volume":"56","author":"Spriggs","year":"1992","journal-title":"Immunol Ser"},{"key":"10.1111\/bjd.14016-BIB0005|bjd14016-cit-0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1111\/bjd.14016-BIB0006|bjd14016-cit-0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-642-78771-3_11","volume-title":"Skin Cancer: Basic Science, Clinical Research and Treatment","author":"Kr\u00fcger-Krasagakes","year":"1995"},{"key":"10.1111\/bjd.14016-BIB0007|bjd14016-cit-0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"10.1111\/bjd.14016-BIB0008|bjd14016-cit-0008","doi-asserted-by":"crossref","first-page":"507","DOI":"10.18388\/abp.2011_2217","article-title":"Secretion of proinflammatory cytokines by normal human melanocytes in response to lipopolysaccharide","volume":"58","author":"Tam","year":"2011","journal-title":"Acta Biochim Pol"},{"key":"10.1111\/bjd.14016-BIB0009|bjd14016-cit-0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"Cell"},{"key":"10.1111\/bjd.14016-BIB0010|bjd14016-cit-0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0898-6568(01)00262-5","article-title":"TNF receptor subtype signaling: differences and cellular consequences","volume":"14","author":"MacEwan","year":"2002","journal-title":"Cell Signal"},{"key":"10.1111\/bjd.14016-BIB0011|bjd14016-cit-0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol"},{"key":"10.1111\/bjd.14016-BIB0012|bjd14016-cit-0012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1111\/bjd.14016-BIB0013|bjd14016-cit-0013","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","article-title":"TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease","volume":"5","author":"McCoy","year":"2008","journal-title":"J Neuroinflammation"},{"key":"10.1111\/bjd.14016-BIB0014|bjd14016-cit-0014","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/bjd.14016-BIB0015|bjd14016-cit-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00478","article-title":"TNF receptor 2 and disease: autoimmunity and regenerative medicine","volume":"4","author":"Faustman","year":"2013","journal-title":"Front Immunol"},{"key":"10.1111\/bjd.14016-BIB0016|bjd14016-cit-0016","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.0022-202X.2005.23653.x","article-title":"4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo","volume":"124","author":"Kroll","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0017|bjd14016-cit-0017","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","article-title":"Detection of tumor necrosis factor \u03b1 but not tumor necrosis factor \u03b2 in rheumatoid arthritis synovial fluid and serum","volume":"31","author":"Saxne","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0018|bjd14016-cit-0018","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","article-title":"Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy","volume":"39","author":"Grom","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0019|bjd14016-cit-0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/36.1.38","article-title":"Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies","volume":"36","author":"Ca\u00f1ete","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1111\/bjd.14016-BIB0020|bjd14016-cit-0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in\u00a0situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0021|bjd14016-cit-0021","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1572-0241.2002.05914.x","article-title":"Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease","volume":"97","author":"Suenaert","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/bjd.14016-BIB0022|bjd14016-cit-0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1111\/bjd.14016-BIB0023|bjd14016-cit-0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","article-title":"Dendritic cells and cytokines in human inflammatory and autoimmune diseases","volume":"19","author":"Blanco","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1111\/bjd.14016-BIB0024|bjd14016-cit-0024","first-page":"1219","article-title":"Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance","volume":"148","author":"Le Poole","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1111\/bjd.14016-BIB0025|bjd14016-cit-0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wa\u0144kowicz-Kali\u0144ska","year":"2003","journal-title":"Lab Invest"},{"key":"10.1111\/bjd.14016-BIB0026|bjd14016-cit-0026","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1084\/jem.166.4.991","article-title":"Inhibition of cytotoxic T cell development by transforming growth factor \u03b2 and reversal by recombinant tumor necrosis factor \u03b1","volume":"166","author":"Ranges","year":"1987","journal-title":"J Exp Med"},{"key":"10.1111\/bjd.14016-BIB0027|bjd14016-cit-0027","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.4049\/jimmunol.138.6.1786","article-title":"Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses","volume":"138","author":"Scheurich","year":"1987","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0028|bjd14016-cit-0028","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0029|bjd14016-cit-0029","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1755-148X.2011.00892.x","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation","volume":"24","author":"Dwivedi","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.14016-BIB0030|bjd14016-cit-0030","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1172\/JCI42945","article-title":"Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs","volume":"120","author":"Grinberg-Bleyer","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1111\/bjd.14016-BIB0031|bjd14016-cit-0031","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.4049\/jimmunol.1003372","article-title":"Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis","volume":"186","author":"Biton","year":"2011","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0032|bjd14016-cit-0032","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2011.09.017","article-title":"TNF-alpha: activator or inhibitor of regulatory T cells?","volume":"79","author":"Biton","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1111\/bjd.14016-BIB0033|bjd14016-cit-0033","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","article-title":"Immunologic tolerance maintained by CD25+\u00a0CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance","volume":"182","author":"Sakaguchi","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1111\/bjd.14016-BIB0034|bjd14016-cit-0034","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.14016-BIB0035|bjd14016-cit-0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF agents in the treatment of immune-mediated inflammatory diseases: mechanisms of actions and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1111\/bjd.14016-BIB0036|bjd14016-cit-0036","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists","volume":"151","author":"Mohler","year":"1993","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0037|bjd14016-cit-0037","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","article-title":"Etanercept (Enbrel): update on therapeutic use","volume":"59","author":"Spencer-Green","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.14016-BIB0038|bjd14016-cit-0038","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1111\/bjd.14016-BIB0039|bjd14016-cit-0039","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.14309\/00000434-200809001-01102","article-title":"Detailing the novel structure of the biopharmaceutical certolizumab pegol","volume":"103","author":"Smith","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. V","key":"10.1111\/bjd.14016-BIB0040|bjd14016-cit-0040","first-page":"A122","article-title":"Pharmacokinetic properties of the anti-TNF agent certolizumab pegol","volume":"55","author":"Baker","year":"2006","journal-title":"Gut"},{"key":"10.1111\/bjd.14016-BIB0041|bjd14016-cit-0041","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.berh.2011.10.004","article-title":"Anti-TNF therapy","volume":"25","author":"Thalayasingam","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1111\/bjd.14016-BIB0042|bjd14016-cit-0042","first-page":"72","article-title":"Tumor necrosis factors blocking agents: analogies and differences","volume":"83","author":"Benucci","year":"2012","journal-title":"Acta Biomed"},{"key":"10.1111\/bjd.14016-BIB0043|bjd14016-cit-0043","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomized, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.14016-BIB0044|bjd14016-cit-0044","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/bjd.14016-BIB0045|bjd14016-cit-0045","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0046|bjd14016-cit-0046","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0047|bjd14016-cit-0047","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliot","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/bjd.14016-BIB0048|bjd14016-cit-0048","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.14016-BIB0049|bjd14016-cit-0049","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14016-BIB0050|bjd14016-cit-0050","first-page":"18","article-title":"Treatment of psoriasis with adalimumab","volume":"32","author":"Pitarch","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.14016-BIB0051|bjd14016-cit-0051","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2032 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14016-BIB0052|bjd14016-cit-0052","first-page":"S371","article-title":"Successful treatment of severe psoriatic arthritis with infliximab","volume":"42","author":"Antoni","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.14016-BIB0053|bjd14016-cit-0053","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/bjd.14016-BIB0054|bjd14016-cit-0054","first-page":"CD003574","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","volume":"1","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.14016-BIB0055|bjd14016-cit-0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/bjd.14016-BIB0056|bjd14016-cit-0056","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/1523-1747.ep12476645","article-title":"Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation","volume":"100","author":"Le Poole","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0057|bjd14016-cit-0057","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Reviewed classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1111\/bjd.14016-BIB0058|bjd14016-cit-0058","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site","volume":"80","author":"Wijngaard","year":"2000","journal-title":"Lab Invest"},{"key":"10.1111\/bjd.14016-BIB0059|bjd14016-cit-0059","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1111\/bjd.14016-BIB0060|bjd14016-cit-0060","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumor necrosis factor alpha (TNF-\u03b1) and interleukin 1 alpha (IL1-\u03b1) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.14016-BIB0061|bjd14016-cit-0061","first-page":"849","article-title":"Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis","volume":"24","author":"Moretti","year":"2009","journal-title":"Histol Histopathol"},{"key":"10.1111\/bjd.14016-BIB0062|bjd14016-cit-0062","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/exd.12621","article-title":"Cytosolic dsDNA triggers apoptosis and pro-inflammatory cytokine production in normal human melanocytes","volume":"24","author":"Wang","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1111\/bjd.14016-BIB0063|bjd14016-cit-0063","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00403-012-1269-6","article-title":"Over-expression of tumor necrosis factor-? in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study","volume":"304","author":"Attwa","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/bjd.14016-BIB0064|bjd14016-cit-0064","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-\u03b1 in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1111\/bjd.14016-BIB0065|bjd14016-cit-0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0923-1811(02)00151-2","article-title":"Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo","volume":"31","author":"Tu","year":"2003","journal-title":"J Dermatol Sci"},{"key":"10.1111\/bjd.14016-BIB0066|bjd14016-cit-0066","doi-asserted-by":"crossref","first-page":"e52298","DOI":"10.1371\/journal.pone.0052298","article-title":"Increased tumor necrosis factor (TNF)-\u03b1 and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo","volume":"7","author":"Laddha","year":"2012","journal-title":"PLoS One"},{"key":"10.1111\/bjd.14016-BIB0067|bjd14016-cit-0067","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0019-5154.92668","article-title":"Serum concentration of IL-6, IL-2, TNF-\u03b1, and IFN \u03b3 in vitiligo patients","volume":"57","author":"Singh","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1111\/bjd.14016-BIB0068|bjd14016-cit-0068","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0069|bjd14016-cit-0069","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-\u03b3 inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.14016-BIB0070|bjd14016-cit-0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/1523-1747.ep12460991","article-title":"Interleukins 1\u03b1 and 6 and tumor necrosis factor \u03b1 are paracrine inhibitors of human melanocyte proliferation and melanogenesis","volume":"96","author":"Swope","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0071|bjd14016-cit-0071","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.14016-BIB0072|bjd14016-cit-0072","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/sj.jid.5700900","article-title":"Impaired PI3K\/Akt activation-mediated NF-\u03baB inactivation under elevated TNF-\u03b1 is more vulnerable to apoptosis in vitiliginous keratinocytes","volume":"127","author":"Kim","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0073|bjd14016-cit-0073","doi-asserted-by":"crossref","first-page":"e81736","DOI":"10.1371\/journal.pone.0081736","article-title":"Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility","volume":"8","author":"Laddha","year":"2013","journal-title":"PLoS One"},{"key":"10.1111\/bjd.14016-BIB0074|bjd14016-cit-0074","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"10.1111\/bjd.14016-BIB0075|bjd14016-cit-0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab","volume":"216","author":"Simon","year":"2008","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1111\/bjd.14016-BIB0076|bjd14016-cit-0076","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.2165\/1153424-S0-000000000-00000","article-title":"A patient with psoriasis and vitiligo treated with etanercept","volume":"11","author":"Campanati","year":"2010","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/bjd.14016-BIB0077|bjd14016-cit-0077","first-page":"AB121","article-title":"Repigmentation of chronic generalized vitiligo following etanercept therapy for seronegative inflammatory arthritis","volume":"62","author":"Tolaymat","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.14016-BIB0078|bjd14016-cit-0078","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/dth.12002","article-title":"Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab","volume":"26","author":"Maruthappu","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1111\/bjd.14016-BIB0079|bjd14016-cit-0079","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000081494","article-title":"Infliximab-induced vitiligo","volume":"210","author":"Ramirez-Hernandez","year":"2005","journal-title":"Dermatology"},{"key":"10.1111\/bjd.14016-BIB0080|bjd14016-cit-0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajg.2011.03.001","article-title":"Vitiligo in a patient receiving infliximab for refractory ulcerative colitis","volume":"12","author":"Ismail","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"10.1111\/bjd.14016-BIB0081|bjd14016-cit-0081","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3899\/jrheum.100968","article-title":"Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy","volume":"38","author":"Lahita","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.14016-BIB0082|bjd14016-cit-0082","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000324619","article-title":"Vitiligo during treatment of Crohn's disease with adalimumab: adverse effect or co-occurrence?","volume":"3","author":"Posada","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"10.1111\/bjd.14016-BIB0083|bjd14016-cit-0083","first-page":"217","article-title":"New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.14016-BIB0084|bjd14016-cit-0084","first-page":"801","article-title":"Aubin F [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab]","volume":"140","author":"Toissirot","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/bjd.14016-BIB0085|bjd14016-cit-0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis - a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1111\/bjd.14016-BIB0086|bjd14016-cit-0086","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1136\/annrheumdis-2014-eular.2560","article-title":"New onset vitiligo under biologic agents: a case series","volume":"73","author":"Mery-Bossard","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.14016-BIB0087|bjd14016-cit-0087","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1111\/bjd.14016-BIB0088|bjd14016-cit-0088","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.annder.2009.12.003","article-title":"[Cutaneous events during anti-TNF-\u03b1 therapy: a prospective observational study of 41 cases]","volume":"137","author":"Bonnet","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/bjd.14016-BIB0089|bjd14016-cit-0089","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/acr.22096","article-title":"Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases","volume":"65","author":"Hern\u00e1ndez","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1111\/bjd.14016-BIB0090|bjd14016-cit-0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2011.01.015","article-title":"Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues","volume":"139","author":"Bos\u00e8","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1111\/bjd.14016-BIB0091|bjd14016-cit-0091","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2133.2007.07945.x","article-title":"Antitumour necrosis factor-\u03b1 chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function","volume":"157","author":"Bedini","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14016-BIB0092|bjd14016-cit-0092","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0001-7310(07)70129-1","article-title":"[Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumour necrosis factor-\u03b1 with etanercept]","volume":"98","author":"Mahiques","year":"2007","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/bjd.14016-BIB0093|bjd14016-cit-0093","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0002-9440(10)65109-7","article-title":"Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis","volume":"155","author":"Nickoloff","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1111\/bjd.14016-BIB0094|bjd14016-cit-0094","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.12034","article-title":"Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo","volume":"168","author":"Benzekri","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.14016-BIB0095|bjd14016-cit-0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: an autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1111\/bjd.14016-BIB0096|bjd14016-cit-0096","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/370650a0","article-title":"Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathway","volume":"370","author":"Lowin","year":"1994","journal-title":"Nature"},{"key":"10.1111\/bjd.14016-BIB0097|bjd14016-cit-0097","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nri819","article-title":"Cytotoxic T lymphocytes: all roads lead to death","volume":"2","author":"Barry","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/bjd.14016-BIB0098|bjd14016-cit-0098","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4049\/jimmunol.161.3.1220","article-title":"Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas\/Fas ligand-independent mechanisms for tumor killing","volume":"161","author":"Rivoltini","year":"1998","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0099|bjd14016-cit-0099","doi-asserted-by":"crossref","first-page":"14899","DOI":"10.1074\/jbc.272.23.14899","article-title":"Synergy between interferon-\u03b3 and tumor necrosis factor-\u03b1 in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor \u03baB","volume":"272","author":"Ohmori","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1111\/bjd.14016-BIB0100|bjd14016-cit-0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/1523-1747.ep12478093","article-title":"Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines","volume":"95","author":"Yohn","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0101|bjd14016-cit-0101","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2133.1998.02550.x","article-title":"Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules","volume":"139","author":"Hedley","year":"1998","journal-title":"Br J Dermatol"},{"issue":"2 Suppl.","key":"10.1111\/bjd.14016-BIB0102|bjd14016-cit-0102","doi-asserted-by":"crossref","first-page":"191S","DOI":"10.1038\/jid.1993.12","article-title":"Influence of inflammatory mediators and cytokines on human melanocyte function","volume":"100","author":"Morelli","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.14016-BIB0103|bjd14016-cit-0103","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1089\/jir.2012.0171","article-title":"Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo","volume":"33","author":"Dwivedi","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1111\/bjd.14016-BIB0104|bjd14016-cit-0104","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.4049\/jimmunol.151.12.7284","article-title":"A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders","volume":"151","author":"Le Poole","year":"1993","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0105|bjd14016-cit-0105","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4049\/jimmunol.0902778","article-title":"Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice","volume":"184","author":"Gregg","year":"2010","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0106|bjd14016-cit-0106","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0","article-title":"Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation","volume":"32","author":"Nakajima","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1111\/bjd.14016-BIB0107|bjd14016-cit-0107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.it.2003.12.005","article-title":"Chemokines: multiple levels of leukocyte migration control","volume":"25","author":"Moser","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1111\/bjd.14016-BIB0108|bjd14016-cit-0108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+\u00a0CD25+ T regulatory cells","volume":"179","author":"Chen","year":"2007","journal-title":"J Immunol"},{"key":"10.1111\/bjd.14016-BIB0109|bjd14016-cit-0109","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate Treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J Invest Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14016","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.14016\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T21:50:02Z","timestamp":1691790602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/173\/3\/641\/6627485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14016","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725620299.793522583","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,25]]}}}